Skip to main navigation Skip to search Skip to main content

A randomized, phase 2A, double-blind, placebo-controlled study of the efficacy and safety of CP-601, 927 augmentation of anti-depressant therapy in major depression

Project: Research

Project Details

StatusFinished
Effective start/end date06/1/10 → 11/30/14

Funding

  • Pfizer Incorporated: $89,332.68